Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

BACKGROUND: Women with SLE have higher rates of persistent human papilloma virus (HPV) infections and precancerous lesions than healthy women. HPV vaccine is safe and effective in healthy females aged 9–26 years. There are limited data on the safety and immunogenicity of HPV vaccine in females with...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Soybilgic, Arzu, Onel, Karen B, Utset, Tammy, Alexander, Kenneth, Wagner-Weiner, Linda
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2013
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751269/
https://ncbi.nlm.nih.gov/pubmed/23924237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1546-0096-11-29
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы